Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Cancer & Oncology — Weekly Report — November 9, 2026

Home/Health Insights/Cancer & Oncology — November 9 – November 16, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Cancer & Oncology
Updated Monday · November 16, 2026
Cancer & Oncology · November 9 – November 16, 2026

Cancer & Oncology
Weekly Report

This week's data 156 new clinical trials registered across 10 countries, with 18,862 trials actively recruiting patients worldwide.
Week of November 9 – November 16, 2026
  • 156 new clinical trials registered across 10 countries.
  • 18,862 trials actively recruiting patients worldwide.
  • Notable trial: EVEREST-HN-3: Linkage of National Data Sets for Suspected Head-and-neck Cancer Referrals (125000 patients).
  • 3,373 new research papers published.
  • Top cited: "Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck ..." (JCO global oncology, 1 citations).
  • Drug safety: Most reported effect across tracked medications (pembrolizumab, nivolumab, trastuzumab, rituximab, paclitaxel) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · November 9 – November 16, 2026
New Trials This Week
156.
registered Nov 9–Nov 16
Recruiting Now
18,862
active trials seeking patients
Countries
10
with active trials this week
Papers Published
3,373
new studies this week
Phase 3 Trials
7
late-stage trials this week
Fig. 01

Trials by country

Count · November 9 – November 16, 2026
United States
37
China
20
France
15
Spain
9
Not specified
7
Japan
7
Egypt
4
Germany
4
United Kingdom
4
Turkey (Türkiye)
2
0 10 20 30 37
total
Fig. 02

Trials by phase

Distribution · November 9 – November 16, 2026

New clinical trials registered this week for Cancer & Oncology. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

156 trials registered for Cancer & Oncology. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Social Media Perceptions Among Young Adults With Cancer - Online Experiment 2 Cancer & Oncology · UNC Lineberger Comprehensive Cancer Center (NCT07928349) Other Completed 207 United States
02 BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma Cancer & Oncology · Liping Dou (NCT07927842) Phase 1 Not Yet Recruiting 20 China
03 A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer Cancer & Oncology · Eli Lilly and Company (NCT07935317) Phase 2 Not Yet Recruiting 120 United States
04 An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC) Cancer & Oncology · First Affiliated Hospital of Zhejiang University (NCT07937124) Phase 2 Not Yet Recruiting 30 N/A
05 Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma Cancer & Oncology · City of Hope Medical Center (NCT07926906) Other Not Yet Recruiting 30 United States
06 Pectoral Nerve Block Versus Serratus Posterior Superior Intercostal Plane Block for Pain Control After Mastectomy Cancer & Oncology · Bursa City Hospital (NCT07929090) Other Recruiting 78 Turkey (Türkiye)
07 Evaluating the Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With High SULF1 Expression Cancer & Oncology · Sir Run Run Shaw Hospital (NCT07927075) Phase 3 Enrolling By Invitation 17 China
08 Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma Cancer & Oncology · Northwell Health (NCT07927595) Other Recruiting 125 United States
09 Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma Cancer & Oncology · Sohag University (NCT07926633) Other Completed 50 Egypt
10 AI-Assisted Remote Monitoring for Patients With or at Risk of Malignant Bowel Obstruction Cancer & Oncology · Hospital Universitario 12 de Octubre (NCT07931989) Other Not Yet Recruiting 140 Spain
11 Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer Cancer & Oncology · LI FENG (NCT07928882) Other Not Yet Recruiting 224 China
12 Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. Cancer & Oncology · The Center for Clinical and Cosmetic Research (NCT07931664) Phase 2 Recruiting 30 United States
13 Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Cancer & Oncology · Beth Israel Deaconess Medical Center (NCT07925333) Phase 2 Not Yet Recruiting 10 United States
14 PSMA PET/MRI for Predicting and Detecting Prostate Cancer Cancer & Oncology · University of Wisconsin, Madison (NCT07924605) Phase 2 Not Yet Recruiting 120 United States
15 Interferon-α Maintenance in Favorable-Risk AML Cancer & Oncology · Peking University People's Hospital (NCT07925554) Phase 2 Recruiting 30 China
16 [18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases Cancer & Oncology · Telix Pharmaceuticals (Innovations) Pty Limited (NCT07931261) Phase 3 Not Yet Recruiting 381 N/A
17 Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients Cancer & Oncology · First Affiliated Hospital of Guangxi Medical University (NCT07933653) Other Recruiting 68 China
18 ^68Ga-grazytracer PET for In Vivo Visualization of Immune Cell Effector Functions Cancer & Oncology · Peking University Third Hospital (NCT07935174) Other Recruiting 80 China
19 A Study to Establish the Diagnostic Value of the EPISEEK-MPE Liquid Biopsy Assay to Identify Cancer in Pleural Effusion Samples. Cancer & Oncology · University of Arizona (NCT07929584) Other Recruiting 625 United States
20 LIMA1 Immunohistochemistry and Depth of Invasion as Prognostic Biomarkers in Oral Squamous Cell Carcinoma Cancer & Oncology · Turku University Hospital (NCT07934316) Other Enrolling By Invitation 140 Finland
21 A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig Cancer & Oncology · Boehringer Ingelheim (NCT07929051) Phase 3 Not Yet Recruiting 68 Belgium
22 First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma Cancer & Oncology · YGION Biomedical GmbH (NCT07930338) Phase 1 Not Yet Recruiting 15 Austria
23 Gryrotonic Training in Behcet-diseased Elders With Breast Cancer Cancer & Oncology · Cairo University (NCT07929116) Other Recruiting 40 Egypt
24 Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors Cancer & Oncology · University of Michigan Rogel Cancer Center (NCT07934173) Other Not Yet Recruiting 44 N/A
25 A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation Cancer & Oncology · Boehringer Ingelheim (NCT07926334) Phase 1 Not Yet Recruiting 200 United States
26 Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome Cancer & Oncology · City of Hope Medical Center (NCT07926893) Phase 1 Not Yet Recruiting 14 United States
27 A Clinical Study of MHB034C for Injection in Participants With Advanced Solid Tumors Cancer & Oncology · Minghui Pharmaceutical (Shanghai) LTD (NCT07928570) Phase 2 Not Yet Recruiting 400 China
28 HIIT-based Exercise Intervention for Improvement of Immunomodulatory, Cardiopulmonary, and Psychosocial Parameters During Maintenance Therapy of Paediatric Acute Lymphoblastic Leukaemia (HEALL) Cancer & Oncology · University of Erlangen-Nürnberg Medical School (NCT07936786) Other Not Yet Recruiting 108 Germany
29 C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV Cancer & Oncology · University of California, San Diego (NCT07925307) Other Recruiting 750 Kenya
30 KRAS G12D-specific Immune Effector Cells Targeting KRAS G12D-positive Solid Tumors Cancer & Oncology · Shenzhen Geno-Immune Medical Institute (NCT07924449) Other Not Yet Recruiting 30 China
31 A Study of LY4336619 in Adult Participants With Advanced Solid Tumors Cancer & Oncology · Eli Lilly and Company (NCT07928258) Phase 1 Not Yet Recruiting 370 United States
32 A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma Cancer & Oncology · CSPC Megalith Biopharmaceutical Co.,Ltd. (NCT07925021) Phase 3 Recruiting 424 China
33 Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL) Cancer & Oncology · Shanghai Tongji Hospital, Tongji University School of Medicine (NCT07934537) Phase 4 Recruiting 20 China
34 Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes Cancer & Oncology · The Affiliated People's Hospital of Ningbo University (NCT07932873) Phase 3 Not Yet Recruiting 10 N/A
35 A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients Cancer & Oncology · Centre Leon Berard (NCT07936422) Phase 2 Not Yet Recruiting 200 France
36 Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS Cancer & Oncology · Kura Oncology, Inc. (NCT07929740) Phase 1 Not Yet Recruiting 126 N/A
37 Myo-Inositol and D-Chiro-Inositol Versus Metformin for Treating Anovulation in Women With Polycystic Ovary Syndrome Cancer & Oncology · Fauji Foundation Hospital (NCT07931625) Other Completed 90 Pakistan
38 EVEREST-HN-3: Linkage of National Data Sets for Suspected Head-and-neck Cancer Referrals Cancer & Oncology · Royal Marsden NHS Foundation Trust (NCT07933588) Other Active Not Recruiting 125,000 United Kingdom
39 Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring Cancer & Oncology · H. Lee Moffitt Cancer Center and Research Institute (NCT07930182) Phase 2 Recruiting 56 United States
40 SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3) Cancer & Oncology · Fudan University (NCT07933679) Phase 3 Not Yet Recruiting 394 China
41 CCS Transitions to Adult Care Cancer & Oncology · University of Texas Southwestern Medical Center (NCT07934329) Other Not Yet Recruiting 100 United States
42 Preoperative Calorie Restriction and Exercise in Patients With Obesity Undergoing Colorectal Cancer Resection Cancer & Oncology · Universidad de Granada (NCT07928076) Other Not Yet Recruiting 20 N/A
43 A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients Cancer & Oncology · Beijing InnoCare Pharma Tech Co., Ltd. (NCT07925190) Phase 3 Recruiting 318 China
44 Comparison of NMTCuff and Standard TOF in Gynecologic Oncology Surgery (NMTCUFF-TOF) Cancer & Oncology · Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital (NCT07925463) Other Recruiting 45 Turkey (Türkiye)
45 DECISIVE Tool Pilot Trial Cancer & Oncology · Yale University (NCT07933484) Other Not Yet Recruiting 20 United States
46 Diagnostic Accuracy of Fine Needle Aspiration Cytology (FNAC) Compared to TI-RADS 3 in the Evaluation of Thyroid Nodules Cancer & Oncology · Sohag University (NCT07928284) Other Enrolling By Invitation 30 Egypt
47 A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis Cancer & Oncology · Affiliated Hospital of Nantong University (NCT07925632) Other Not Yet Recruiting 80 China
48 A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer Cancer & Oncology · Ruijin Hospital (NCT07928362) Other Not Yet Recruiting 56 China
49 Single Versus Double Stapling and Two Purse-String Techniques in Rectal Cancer Surgery Cancer & Oncology · Alexandria University (NCT07929415) Other Recruiting 124 Egypt
50 Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC Cancer & Oncology · Harbin Medical University (NCT07935226) Phase 2 Not Yet Recruiting 100 N/A
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Cancer & Oncology. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
nivolumab Off Label Use 820
trastuzumab Myelosuppression 707
rituximab Off Label Use 5,218
paclitaxel Myelosuppression 1,062

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Cancer & Oncology. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

3,373 papers

Recently published peer-reviewed studies related to Cancer & Oncology, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 SF3A3 Promotes Hepatocellular Carcinoma Progression and Regulates Jagged 2-Notch 1 Signaling. Yang J et al. 10.1002/mc.70204
View abstract

Splicing factor 3a subunit 3 (SF3A3) has been reported to be dysregulated in various cancers. Previous studies have suggested its prognostic value in hepatocellular carcinoma (HCC), but the specific effect and molecular mechanisms remain to be further explored. Therefore, this study aims to investigate the role of SF3A3 in HCC pathogenesis. SF3A3 expression was compared between HCC and normal tissues using public databases and immunohistochemistry, and its clinical significance was evaluated by clinicopathological, ROC, and Kaplan-Meier analyses. Differential expression and enrichment analyses explored potential biological functions. In vitro assays assessed the effects of SF3A3 knockdown on HCC cell proliferation, migration, and invasion. RNA sequencing, molecular validation, and rescue experiments investigated the underlying mechanism, while a nude mouse xenograft model evaluated its role in vivo. SF3A3 was significantly upregulated in HCC and was associated with adverse clinicopathological features. SF3A3 expression showed discriminatory ability between HCC and normal liver tissues in retrospective transcriptomic cohorts and was associated with poor survival. Functional enrichment analyses linked SF3A3 to cell cycle regulation and DNA replication, while SF3A3 knockdown suppressed HCC cell proliferation, migration, and invasion in vitro. Transcriptomic profiling further identified Notch signaling as a potential downstream pathway, and this association was supported by rescue experiments. In conclusion, SF3A3 promotes tumor progression and is associated with regulation of Jagged 2-Notch 1 signaling. These findings provide preliminary insight into the molecular mechanisms underlying SF3A3-mediated HCC progression and support further investigation of its potential clinical and therapeutic relevance.

Molecular carcinogenesis 2026 Nov 15 PubMed
02 Effects of Resveratrol Supplementation on Exercise-Induced Muscle Damage: A Narrative Review. Yang SL et al. 10.1093/nutrit/nuag103
View abstract

Exercise-induced muscle damage (EIMD) is a common consequence of high-intensity or unfamiliar physical activity and can lead to muscle soreness, inflammation, oxidative stress, and temporary loss of muscle function. Although various interventions have been explored to alleviate EIMD, resveratrol (RES), a natural polyphenolic compound found in grapes, berries, and other plants, has attracted attention due to its potential antioxidant and anti-inflammatory properties. This review aims to explore the effects of RES on EIMD in terms of its impact on muscle recovery, inflammation, and oxidative stress markers. This review synthesizes the results of preclinical and clinical studies and highlights the timing, dosage, and efficacy of exercise-associated RES. Although the results are promising, with several studies reporting reduced muscle damage and improved recovery, inconsistencies in RES administration timing, dosage, and bioavailability require further investigation. Understanding these factors is critical to optimizing the therapeutic potential of RES in both the exercise and clinical settings. Finally, the review summarizes the potential of RES as a safe and effective intervention for EIMD and implications for future research.

Nutrition reviews 2026 Nov 15 PubMed
03 Mapping Two Decades of KRAS-Targeted Drug Development in Cancer: A Bibliometric Analysis of Scientific Evolution and Emerging Therapeutic Trends. Aly AS et al. 10.1007/s43441-026-01080-1
View abstract

AIM: To characterize the global research landscape, collaboration patterns, intellectual structure, and emerging hotspots of KRAS-targeted therapy in cancer using bibliometric methods. METHODS: Web of Science Core Collection records from 1991 to 2026 were retrieved with a validated search (benchmark recall 25/25) and analyzed after restriction to articles and reviews. Bibliometrix, VOSviewer, and R were used to evaluate annual output, citations, country and institutional activity, journal quartiles, international collaboration, source distribution, author productivity, co-occurrence networks, co-citation structure, co-authorship, and trend topics. RESULTS: The final dataset included 4599 publications, comprising 3926 articles and 673 reviews, across 868 sources and 104,438 cited references. Annual output increased gradually through the 2010s and accelerated after 2020, rising by 85% to its highest level in 2025. Country-affiliation occurrence frequency was highest for the USA and China, while country-level citation impact was led by the USA; US papers appeared more often in first-quartile journals (66.6% vs. 51.2%) and were more often internationally co-authored (26.9% vs. 15.5%), whereas China's first-quartile share rose from 40.4% before 2016 to 55.1% in 2021-2026. Major sources included Cancer Research, Cancers, Oncogene, Clinical Cancer Research, and Oncotarget. Trend-topic and co-occurrence analyses showed a shift from farnesyltransferase inhibition and anti-EGFR biomarker research toward KRAS G12C, sotorasib, efficacy, acquired resistance, and KRAS G12D. CONCLUSION: KRAS-targeted therapy research has evolved from a pathway-centered and indirect-targeting literature, through a biomarker-dominated period, into a rapidly expanding precision-oncology field whose growth followed clinical validation of direct inhibition. Current bibliometric patterns highlight direct mutant KRAS inhibition, resistance biology, and allele-specific targeting beyond G12C as major research frontiers, with pancreatic cancer translation and international collaboration as priorities. These findings should be interpreted as indicators of research activity and intellectual structure rather than evidence of therapeutic efficacy.

Therapeutic innovation & regulatory science 2026 Nov 15 PubMed
04 MRI-defined necrosis morphology, circulating immune profiles and survival in glioblastoma. Gagliardi F et al. 10.1007/s11060-026-05872-1
View abstract

PURPOSE: Necrosis is a defining feature and an active hypoxic niche implicated in immune escape and treatment resistance in glioblastoma (GBM). We asked whether MRI-defined necrosis morphology is associated with circulating immune profiles and overall survival (OS). METHODS: We retrospectively studied 111 patients with newly diagnosed IDH-wildtype GBM resected in 2018-2024. Preoperative necrosis was classified visually as classic confluent or multiloculated. Two blinded readers reclassified all cases independently. Immune subsets were assessed by flow cytometry (n = 59, 48/11 classic/multiloculated) and plasma cytokines by multiplex immunoassay (n = 54, 45/9). All 28 immune analytes were exploratory, corrected across the panel. OS from surgery was analyzed with Kaplan-Meier and Cox models, including treatment and small-sample sensitivity analyses. RESULTS: Inter-reader agreement was kappa = 0.883. Multiloculated morphology was associated with longer OS (median, 17.4 vs. 14.4 months; HR, 0.55, 95% CI, 0.31-0.98, p = 0.041), including after multivariable adjustment (n = 94; HR, 0.42, 0.22-0.81, p = 0.010; Firth-penalized, 0.44, p = 0.007), exclusion of untreated patients and early deaths, and restriction to completed chemoradiation (HR, 0.37, 0.16-0.84, p = 0.018). Classic morphology was associated with fewer conventional dendritic cells (cDCs) (0.15% vs. 0.41%, p = 0.006), more mature natural killer cells (p = 0.022), and lower granzyme B, IL-2, IL-4, IL-6, and IL-10, but no difference survived correction (lowest q = 0.088). Multiloculated patients were younger (57.2 vs. 64.3 years, p = 0.032). The cDC association did not persist after adjustment for deep-seated location (p = 0.124). CONCLUSIONS: Multiloculated necrosis was associated with longer OS after adjustment for established prognostic factors, which requires external validation. Circulating immune differences were exploratory and could not be separated from tumor location. CLINICAL TRIAL NUMBER: Not applicable.

Journal of neuro-oncology 2026 Nov 15 PubMed
05 Exploration of Extravascular Tissue and Synovial Fluid Distribution of Extended Half-Life Factor IX Concentrates by Physiologically Based Pharmacokinetic Modelling. Koopman SF et al. 10.1007/s40262-026-01716-3
View abstract

BACKGROUND: Extended half-life factor IX (EHL-FIX) concentrates are a mainstay of prophylactic treatment in haemophilia B due to their prolonged plasma half-life and less frequent administration. Plasma FIX activity levels do not necessarily correlate with haemostatic efficacy, possibly due to its extravascular tissue distribution while still contributing to haemostasis. Importantly, tissue-specific exposure of EHL-FIX concentrates remains insufficiently characterised. OBJECTIVES: We aimed to characterise and compare FIX distribution across plasma, extravascular and synovial tissue using physiologically based pharmacokinetic (PBPK) modelling. METHODS: PBPK models were developed in PK-Sim/MoBi to simulate plasma concentration-time profiles following a 50 IU/kg dose of eftrenonacog alfa (rFIX-Fc), albutrepenonacog alfa (rIX-FP) and nonacog beta pegol (N9-GP). The models incorporated binding affinity (Kd) to collagen type IV (Col4), the neonatal Fc receptor (FcRn) and a vascular endothelial binding partner. A synovium module was implemented to estimate joint-specific exposure. RESULTS: Predicted extravascular distribution profiles differed markedly among EHL-FIX concentrates. rFIX-Fc demonstrated the greatest extravascular distribution, followed by rIX-FP, whereas N9-GP showed minimal distribution. For rFIX-Fc and rIX-FP, highest exposure was predicted in the spleen, lung and kidney. Kd was higher for rFIX-Fc than rIX-FP, while Kd was comparable. No Kd for N9-GP was identified. Synovial fluid concentration predictions indicated highest exposure for rFIX-Fc, modest exposure for rIX-FP and limited exposure for N9-GP. CONCLUSIONS: The constructed PBPK models provide a mechanistic framework for predicting distinct plasma and tissue-specific distribution profiles for three EHL-FIX concentrates, offering a quantitative basis for exploration of the relationship between extravascular and synovial exposure and bleeding outcomes in haemophilia B.

Clinical pharmacokinetics 2026 Nov 15 PubMed
06 Abatacept-Associated behavioral, inflammatory, and immunohistochemical changes in a rotenone-induced rat model of parkinsonism. Cankara FN et al. 10.1007/s11033-026-13141-7
View abstract

BACKGROUND: Neuroinflammation and peripheral immune dysregulation are implicated in Parkinson's disease, supporting evaluation of immunomodulatory interventions. We investigated outcomes associated with abatacept administered before rotenone exposure, alone or combined with L-DOPA/benserazide administered concurrently with rotenone, in a rat model of parkinsonism. METHODS AND RESULTS: Thirty male Wistar rats were randomly assigned to five groups: control, rotenone, rotenone plus abatacept, rotenone plus L-DOPA/benserazide, and combined treatment. Rotenone and L-DOPA/benserazide were administered concurrently for 14 days; abatacept was administered twice, beginning 48 h before rotenone. Motor performance and serum IL-10 and TNF-α were assessed. TH and pSer129 α-synuclein immunopositivity in the substantia nigra and pSer129 α-synuclein and TNF-α immunopositivity in peripheral tissues were evaluated semi-quantitatively. Compared with rotenone, abatacept increased rearing, ambulation, and serum IL-10 and decreased serum TNF-α, without significantly altering rotarod performance or nigral immunopositivity. L-DOPA improved all motor measures and increased serum IL-10 but did not significantly alter serum TNF-α or nigral immunopositivity. Combined treatment improved all motor measures, increased serum IL-10 and nigral TH immunopositivity, decreased serum TNF-α, and reduced pSer129 α-synuclein immunopositivity in four peripheral tissues and TNF-α immunopositivity in the liver and jejunum. Serum TNF-α was lower with abatacept than with L-DOPA. Compared with L-DOPA, combined treatment additionally affected only ambulation and serum TNF-α. CONCLUSIONS: Abatacept was associated with selected motor and cytokine changes in experimental parkinsonism. Combined treatment showed a broader pattern of changes relative to rotenone, but its advantages over L-DOPA were outcome-specific. Peripheral pSer129 α-synuclein findings represent exploratory changes in immunoreactivity rather than evidence of altered α-synuclein aggregation. These findings, obtained under a pretreatment/concurrent administration design, support further investigation but do not establish therapeutic efficacy after parkinsonian pathology has developed, a generalized combination benefit, or an underlying immune mechanism.

Molecular biology reports 2026 Nov 15 PubMed
07 Mitochondrial metabolism and oxygen dynamics in photodynamic therapy: mechanisms, challenges, and therapeutic strategies. Rezvani Dehaghani F et al. 10.1007/s11033-026-13147-1
View abstract

Photodynamic therapy (PDT) is a minimally invasive method for cancer treatment based on the triad of a photosensitizing agent (PS), an appropriate wavelength of light, and tissue oxygen, which works by producing reactive oxygen species (especially singlet oxygen,[Formula: see text]). However, rapid photochemical oxygen consumption during PDT, combined with ongoing oxygen utilization by mitochondrial respiration, can exacerbate local hypoxia and compromise singlet oxygen generation in solid tumors. In this review study, we examine the relationship between mitochondrial metabolism (OXPHOS and the electron transport chain), oxygen consumption, and the efficacy of PDT. We also discuss the metabolic flexibility of cancer cells (the shift between the Warburg effect and oxidative phosphorylation) and the impact of the hypoxia axis (HIF-1/2α) on treatment resistance. So far, strategies such as mitochondrial respiration inhibition, mitochondria-targeted nanoplatforms, and redox manipulation have been implemented to address this issue. Reprogramming mitochondrial metabolism along with smart drug delivery systems is considered a promising approach to overcoming hypoxia and achieving personalized treatments in PDT, although proving the clinical efficacy of these strategies will require more extensive experimental studies and trials in the future.

Molecular biology reports 2026 Nov 15 PubMed
08 Tumo​r-associated macrophages in ovarian, prostate, thyroid and pancreatic neuroendocrine tumors: molecular crosstalk and therapeutic perspectives. Patel D et al. 10.1007/s11033-026-13145-3
View abstract

Tumor-associated macrophages (TAMs) are key regulators of the tumor microenvironment and play dual roles in endocrine cancer progression by exhibiting remarkable functional plasticity beyond the conventional M1/M2 paradigm. Their interactions with tumor cells influence immune evasion, angiogenesis, metastasis, and therapeutic resistance through complex signaling networks and extracellular vesicle-mediated communication. This review summarizes the current understanding of TAM biology across some key endocrine and hormone-dependent cancers, including ovarian, prostate, thyroid, and pancreatic neuroendocrine tumors, highlighting their prognostic significance and molecular mechanisms. We further discuss emerging TAM-targeted therapeutic strategies, including macrophage depletion, immune checkpoint modulation, macrophage reprogramming, and nanoparticle-based approaches. Finally, we outline the challenges associated with clinical translation and emphasize the potential of single-cell and multi-omics technologies to enable precision macrophage-targeted therapies for endocrine cancers, including a summary of recent developments in the field of precision mapping of TAMs.

Molecular biology reports 2026 Nov 15 PubMed
09 Photocatalytic Disruption of Concurrent Redox Axes Elicits Convergent Redox Collapse. Yang X et al. 10.1002/anie.7418410
View abstract

The interconnected antioxidant systems of cancer cells, centered on the glutathione and thioredoxin axes, constitute a promising therapeutic vulnerability. However, simultaneous disruption of both axes by dual-inhibitor regimens is hampered by pharmacokinetic asynchrony. Herein, we report squaraine-based photocatalysts as a single-agent modality that concurrently disrupts these interconnected antioxidant systems in cancer cells. Upon 635 nm light irradiation, IITC depletes intracellular NADPH and GSH through photocatalytic oxidation coupled with type I/II photosensitization. NADPH depletion deprives the reductive coenzyme of thioredoxin reductase in the thioredoxin axis, while glutathione oxidation collapses the central antioxidant axis. Consequently, IITC ablates both antioxidant axes concurrently and exerts potent phototherapeutic anticancer activity in vitro and in vivo. Importantly, during phototherapy IITC undergoes self-immolation into nontoxic degraded fragments, thereby avoiding phototoxicity post-treatment. This self-eliminating, metabolism-targeted photocatalytic strategy establishes a new avenue for safe and efficient cancer phototherapy.

Angewandte Chemie (International ed. in English) 2026 Nov 15 PubMed
10 Feasibility and safety of an automated chyme reinfusion device for high-output stomas and enterocutaneous fistulas in hospitalized adults: A descriptive cohort study. Boros M et al. 10.1002/jpen.70165
View abstract

BACKGROUND: High-output stomas and enterocutaneous fistulas cause dehydration, electrolyte disturbances, malnutrition, and prolonged dependence on parenteral nutrition. Chyme reinfusion may restore distal enteral continuity but remains technically demanding. Our descriptive cohort study evaluated the technical feasibility of chyme reinfusion using an automated chyme reinfusion device in adults with high-output stomas or enterocutaneous fistulas. METHODS: We included consecutive hospitalized postoperative adults who initiated an automated chyme reinfusion device for a high-output stoma or enterocutaneous fistula at Geneva University Hospitals between 2022 and 2025. The primary outcome was technical feasibility, defined as successful use of the device without premature discontinuation due to device-related failure. Secondary outcomes were tolerance, device-related complications, changes in parenteral nutrition requirements, and body weight and serum albumin at baseline and Week 4. RESULTS: Twelve patients were included. Technical feasibility was achieved in 10 (83.3%). Chyme reinfusion was initiated a median of 37 days after surgery and maintained for a median of 42 days. Among 10 patients receiving parenteral nutrition at baseline, it was discontinued in three and reduced in three. Median body weight was 61.7 kg at baseline and 64.6 kg at Week 4. Median serum albumin was 25 and 29.5 g/L, respectively. Reinfusion-related difficulties occurred in nine patients. Two catheter migrations occurred, one causing small-bowel perforation requiring resection. CONCLUSION: Automated chyme reinfusion appears technically feasible in selected patients with high-output stomas or enterocutaneous fistulas, but practical difficulties and device-related complications are common. Prospective studies are needed to define patient selection, safety, and clinical benefit.

JPEN. Journal of parenteral and enteral nutrition 2026 Nov 15 PubMed
11 Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control. Visentin A et al. 10.1002/jha2.70451
View abstract

INTRODUCTION: Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. METHODS: We retrospectively evaluated 679 zanubrutinib-treated patients across 52 Italian centers, with 354 historical ibrutinib-treated controls. Shanafelt AF scores were assessed. RESULTS: Nine zanubrutinib-treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. CONCLUSION: AF was uncommon during zanubrutinib treatment, even in the higher-risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow-up. TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.

EJHaem 2026 Dec PubMed
12 Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. Yan H et al. 10.2147/JHC.S650816
View abstract

BACKGROUND: Evidence for transarterial chemoembolization plus hepatic arterial infusion chemotherapy (TACE-HAIC), lenvatinib, and programmed cell death protein 1 (PD-1) blockade in unresectable hepatocellular carcinoma (uHCC) remains limited. We assessed outcomes associated with tislelizumab or nivolumab combined regimens and conducted an exploratory, nonrandomized comparison between the two treatment groups. PATIENTS AND METHODS: This single-center retrospective cohort study included patients with uHCC who received TACE-HAIC, lenvatinib, and either tislelizumab or nivolumab between February 2021 and October 2025. Best overall response was assessed using RECIST version 1.1 and modified RECIST (mRECIST). Survival outcomes, treatment-emergent adverse events (TEAEs), clinical prognostic factors, and inverse probability of treatment weighting (IPTW) analyses were evaluated. RESULTS: Of 102 screened patients, 83 were ultimately included. Most patients had BCLC stage C disease (98.8%), macrovascular invasion (97.6%), and multiple hepatic lesions (95.2%). The mRECIST-based objective response rate (ORR) and disease control rate (DCR) was 59.0% and 94.0%, respectively; the corresponding RECIST 1.1 rates were 34.9% and 94.0%. Median progression-free survival (PFS) and overall survival (OS) for the entire cohort were 7.6 and 19.2 months, respectively. Median OS was 23.2 months in the nivolumab group and 16.7 months in the tislelizumab group (log-rank P = 0.044), whereas unweighted PFS, ORR, and DCR did not differ significantly between the groups. The IPTW-adjusted OS HR for nivolumab-based vs tislelizumab-based treatment was 0.54 (95% CI 0.31-0.92), attenuating to 0.70 (95% CI 0.35-1.38; P = 0.302) after additional adjustment for treatment initiation period. The corresponding PFS HRs were 0.61 (95% CI 0.38-0.98; P = 0.042) and 0.55 (95% CI 0.28-1.10; P = 0.092), respectively. Grade 3-4 TEAEs occurred in 39.8% of patients. Tumor size was associated with OS in exploratory stepwise models. CONCLUSION: This combination regimen was associated with encouraging outcomes in a selected, high-risk uHCC cohort. However, the exploratory OS difference between nonrandomly assigned PD-1 inhibitor groups remains vulnerable to calendar-time bias and other residual confounders.

Journal of hepatocellular carcinoma 2026 PubMed
13 Cryptogenic Invasive Klebsiella pneumoniae Liver Abscess Syndrome with Occult Colon Cancer: A Case Report. Wang N et al. 10.2147/IDR.S653635
View abstract

BACKGROUND: Invasive liver abscess syndrome (IKLAS) describes liver abscess with extrahepatic metastatic infection. Although the syndrome is associated with hypervirulent (hvKP), its clinical presentation alone does not confirm hypervirulence. Occult colorectal malignancy may be identified during evaluation of apparently cryptogenic infection. CASE PRESENTATION: A 75-year-old man presented with intermittent fever for more than 1 month and right upper abdominal pain. Imaging revealed multiple hepatic abscesses and pulmonary lesions compatible with metastatic infection. was isolated from blood and sputum cultures, supporting a clinical diagnosis of IKLAS. Hypervirulence was clinically suspected but not microbiologically confirmed because capsular serotyping and virulence-gene testing were not performed. The patient had no history of diabetes mellitus or biliary tract disease. Abdominal CT showed irregular wall thickening at the hepatic flexure, and colonoscopy with biopsy confirmed moderately to poorly differentiated adenocarcinoma. Piperacillin-tazobactam and moxifloxacin were associated with clinical improvement and radiologic regression; percutaneous drainage was deferred because of incomplete abscess liquefaction. After infection control, he underwent laparoscopic radical right hemicolectomy (pathological stage pT3N0Mx). No recurrence or distant metastasis was detected at the 9-month postoperative follow-up. CONCLUSION: This case illustrates that apparently cryptogenic IKLAS may be an initial clinical clue to occult colon cancer. Individualized colorectal evaluation may be considered, particularly in patients without common predisposing factors or with suspicious clinical or imaging findings. This single case does not establish causality or support universal screening.

Infection and drug resistance 2026 PubMed
14 Biologic Treatment Outcomes and the Biomarker Potential of Plasma MMP9 in Generalized Pustular Psoriasis: A Real-World Study. Chen J et al. 10.2147/JIR.S641654
View abstract

BACKGROUND: Generalized pustular psoriasis (GPP) is a severe neutrophilic inflammatory disease. Although biologics targeting IL-17A, IL-12/23, and IL-36R are used in clinical practice, their relative effectiveness in real-world has not been fully characterized, and the potential value of plasma MMP9 as a biomarker of disease activity remains unclear. OBJECTIVE: To compare differences in efficacy and safety among biologics targeting IL-17A, IL-12/23, and IL-36R, and to evaluate changes in treatment-related plasma MMP9 levels and their association with disease activity and routine laboratory markers. Additionally, to characterize the cellular expression patterns of MMP9 in GPP lesions using single-cell transcriptomic analysis. METHODS: This retrospective study included patients with GPP who received IL-17A, IL-12/23, or IL-36R inhibitors between July 2019 and May 2025. Clinical outcomes were evaluated over 24 weeks. Plasma MMP9 levels were measured longitudinally and correlated with clinical activity and inflammatory markers. Single-cell RNA sequencing of GPP lesions was performed to characterize the cellular expression pattern of MMP9. RESULTS: A total of 72 patients were included in the clinical effectiveness analysis. After 24 weeks, GPP Area and Severity Index (GPPASI), GPP physician global assessment (GPPGA), and Dermatology Life Quality Index (DLQI) improved significantly from baseline, with IL-36R inhibitors showing the most rapid response, followed by IL-17A and IL-12/23 inhibitors. In patients with available plasma samples (n=13), baseline MMP9 showed the strongest observed correlation with GPPASI among the assessed index (Spearman's r = 0.8736, <0.001), whereas the correlations of GPPASI with C-reactive protein (CRP), white blood cell count (WBC), neutrophil count, and albumin were relatively weak. Single-cell RNA sequencing revealed predominant MMP9 expression in myeloid cells, particularly neutrophils and macrophages. CONCLUSION: Biologics targeting IL-36R, IL-17A, and IL-12/23 provided sustained disease control in GPP. Circulating MMP9 was strongly associated with GPPASI, decreased following biologic treatment, and exhibited a predominantly myeloid expression pattern in GPP lesions, supporting its further evaluation as a candidate disease-activity biomarker.

Journal of inflammation research 2026 PubMed
15 Rethinking Antioxidant Use in Breast Cancer: A Redox Decision-Node Framework for Therapeutic Risk and Translation. Herdiana Y et al. 10.2147/BCTT.S651619
View abstract

Antioxidant supplementation is often viewed as a rational response to oxidative imbalance, yet in cancer this assumption is incomplete. Reactive oxygen species (ROS) function not only as damaging molecules but also as regulators of tumor proliferation, immune interactions, metabolic adaptation, and therapy-induced cell death. This review critically examines antioxidant use in breast cancer through a mechanistic decision-node framework. Because direct clinical evidence on antioxidant combinations in breast cancer is scarce, the framework draws largely on mechanistic, preclinical and indirect clinical evidence, much of it from single-agent studies or non-breast cancer populations, and is intended to generate hypotheses rather than to serve as a validated decision tool. We integrate evidence across therapeutic intent, timing relative to chemotherapy or radiotherapy, treatment backbone, molecular subtype, and tumor redox state, emphasizing four tumor-intrinsic nodes: NRF2/KEAP1-driven cytoprotection and therapy resistance; BACH1 stabilization as an emerging preclinical metastatic risk node; ferroptosis vulnerability, particularly in investigational triple-negative breast cancer settings; and NADPH-dependent antioxidant recycling through glutathione and thioredoxin systems. Tumor microenvironment redox immunology is considered as a contextual modifier. Current evidence supports the strongest near-term rationale for antioxidant-associated approaches in supportive care, whereas tumor-directed adjunctive use remains investigational. We highlight unresolved questions, including biomarker selection, timing relative to chemotherapy or radiotherapy, subtype-specific redox dependencies, and oncological endpoint assessment. Future trials should document antioxidant exposure, define therapeutic intent a priori, incorporate redox biomarkers, and distinguish symptom improvement from tumor-control benefit.

Breast cancer (Dove Medical Press) 2026 PubMed
16 Real-World Toxicity and Hospitalization Outcomes Following Immunotherapy for Malignant Pleural Mesothelioma. David R et al. 10.7759/cureus.119661
View abstract

Introduction Malignant pleural mesothelioma (MPM) is an aggressive disease with poor outcomes despite advances in systemic treatment. Combination immune checkpoint inhibitor therapy with nivolumab and ipilimumab is increasingly used in clinical practice for advanced MPM; however, real-world treatment outcomes and treatment-related toxicities remain important considerations. This study evaluated survival outcomes, treatment response, toxicity, and hospitalization in patients with advanced mesothelioma receiving combination immunotherapy with nivolumab and ipilimumab. Methods We conducted a retrospective cohort study of 24 patients with advanced mesothelioma who received nivolumab and ipilimumab at a tertiary NHS hospital in Birmingham, United Kingdom, between April 2021 and October 2025. Demographic and clinical characteristics, treatment exposure, radiological response, progression-free survival (PFS), overall survival (OS), adverse events, and hospital admissions were reviewed. Survival outcomes were assessed using Kaplan-Meier analysis. Results Twenty-four patients were included, of whom 23 (95.8%) had pleural disease and 14 (58.3%) had an Eastern Cooperative Oncology Group performance status of 1. The median number of treatment cycles was five (range, 1-24). Recorded response categories were progressive disease in 12 patients (50%), stable disease in seven (29.2%), partial response in three (12.5%), and mixed response in two (8.3%). Median PFS was 4.5 months, and median OS was 9.5 months. Grade 3 or higher immune-related adverse events occurred in six patients (25%). Twenty patients (83.3%) experienced at least one hospital admission, with 36 admission episodes recorded. Admissions were attributed to immunotherapy-related adverse effects in 16 patients and disease-related or other non-immune complications in four patients. Conclusions Outcomes following nivolumab and ipilimumab varied considerably in this real-world cohort. Hospital admissions occurred in a substantial proportion of patients and were attributed to both immunotherapy-related adverse effects and disease-related complications. These findings highlight the importance of careful assessment, toxicity recognition, and multidisciplinary management during treatment.

Cureus 2026 Nov PubMed
17 Burden and Temporal Trends of Female Breast Cancer Attributable to High Fasting Plasma Glucose in China and G20 Countries, 1990-2023: An Analysis of the Global Burden of Disease Study 2023. Zheng J et al. 10.2147/IJWH.S648762
View abstract

OBJECTIVE: This study aimed to characterise the burden, temporal trends and geographical variation of female breast cancer attributable to high fasting plasma glucose (HFPG) in China and G20 countries from 1990 to 2023, and to provide evidence for targeted prevention and control strategies. METHODS: Attributable burden estimates from the Global Burden of Disease Study 2023 (GBD 2023) were used to compare HFPG-attributable female breast cancer mortality and disability-adjusted life-years (DALYs) between China and G20 countries from 1990 to 2023. Joinpoint regression and age-period-cohort (APC) analyses assessed temporal trends in this burden. Spearman's correlation analysis explored its association with the Socio-demographic index (SDI) gradient, and decomposition analysis quantified the separate contributions of population ageing, population growth, and epidemiological transitions to changes in burden. A Bayesian age-period-cohort (BAPC) model was applied to project these burden estimates for 2024-2038. RESULTS: From 1990 to 2023, HFPG-attributable breast cancer deaths, as estimated by the GBD comparative risk assessment framework, increased by 111.19% (15,672 additional deaths) across G20 countries, while age-standardised mortality rate (ASMR) and age-standardised DALY rate (ASDR) modestly decreased by 8.33% and 7.54%. In China, attributable deaths rose by 55.18% (1842 additional deaths), with ASMR and ASDR falling sharply by 38.89% and 43.75%. Marked heterogeneity was observed across G20 countries. Both ASMR and ASDR showed a rebound between 2020 and 2023 in China and G20 countries. The SDI exhibited an inverted U-shaped association with ASMR and ASDR. Population growth and ageing were key contributors to rising attributable burden. BAPC projections suggest that the absolute burden will continue to increase over the subsequent 15 years. CONCLUSION: Over the past 30 years, the absolute burden of female breast cancer attributed to HFPG in China and G20 countries has shown an upward trend. Based on BAPC projections, this burden may continue to increase over the next 15 years. Given the significant differences in the characteristics of the transnational burden, countries should adopt targeted public health interventions tailored to their national conditions, such as population size, social development level, and healthcare environment, to address this potential trend.

International journal of women's health 2026 PubMed
18 Nanotechnology-Enabled Strategies in Thyroid Disorders: From Molecular Imaging to Targeted Therapy and Drug Delivery. Shi Y et al. 10.2147/IJN.S629490
View abstract

Thyroid disorders, including hypothyroidism, hyperthyroidism, autoimmune thyroid disorders, goiter, and thyroid cancer, represent major global health concerns. Conventional diagnostic and treatment modalities have been clinically validated, but shortcomings include poor specificity and sensitivity in diagnosis, general toxicity, and lack of capacity for selective delivery under certain pathologies. Nanotechnology appears promising to overcome some of these limitations by using nanoscale imaging probes, biosensors, drug-delivery systems, and targeting/stimuli responsive systems. Various nanoparticle platforms, including liposomes, polymeric nanoparticles, metal/silica nanoparticles, micelles, nanogels, and carbon-based nanomaterials, have been developed to facilitate the diagnostics, imaging, drug delivery, and therapy of thyroid disorders. Unfortunately, existing scientific information regarding nanotechnology-based strategies for thyroid disease management is heterogeneous, and mainly comes from in vitro experiments and animal models with insufficient clinical verification. Therefore, enhanced diagnostic and/or therapeutic outcomes achieved experimentally should not be assumed to provide any proven benefits for patients. The present narrative review provides an overview of the advances in the use of nanotechnology for thyroid disorders with a particular focus on their diagnostic and imaging performance, therapy, safety, and translational potential.

International journal of nanomedicine 2026 PubMed
19 Probiotics and Prebiotics in Restoring Gastrointestinal Microbiota Dysbiosis: Emerging Alternatives to Antibiotic Therapy. Goa T et al. 10.1155/ijfo/6956918
View abstract

The human gastrointestinal (GI) microbiota is a complex and dynamic microbial ecosystem that plays a fundamental role in maintaining host metabolism, immune homeostasis, intestinal barrier integrity, and protection against pathogenic microorganisms. Disruption of this microbial community, known as gut dysbiosis, has been implicated in the pathogenesis of numerous GI and systemic diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), infection, obesity, type 2 diabetes mellitus, colorectal cancer, and nonalcoholic fatty liver disease. Although antibiotics remain indispensable for the treatment of bacterial infections, their indiscriminate use frequently disrupts gut microbial composition, reduces microbial diversity, promotes opportunistic pathogen overgrowth, and accelerates the emergence of antimicrobial resistance. These limitations have stimulated increasing interest in microbiota-targeted interventions as safer and more sustainable therapeutic strategies. Probiotics and prebiotics have emerged as promising approaches for restoring gut microbial homeostasis through complementary mechanisms. Probiotics inhibit pathogen colonization, enhance intestinal barrier function, produce antimicrobial metabolites, and modulate host immune responses. Prebiotics selectively stimulate the growth and metabolic activity of beneficial microorganisms, promoting the production of short-chain fatty acids (SCFAs) that support intestinal and systemic health. Increasing evidence from experimental studies, randomized clinical trials, and meta-analyses demonstrates that these microbiota-directed interventions can reduce antibiotic-associated diarrhea, improve symptoms of IBD and IBS, enhance eradication, decrease recurrence of infection, and contribute to the management of several metabolic disorders. Despite these promising findings, important challenges remain regarding strain specificity, optimal dosage, treatment duration, product standardization, regulatory oversight, and interindividual variability in treatment response. Emerging advances in metagenomics, metabolomics, artificial intelligence, and precision medicine are facilitating the development of personalized microbiome-based therapies that may further enhance clinical outcomes. This review critically summarizes the current understanding of GI microbiota dysbiosis, discusses the mechanisms through which probiotics and prebiotics restore microbial balance, evaluates their clinical applications as alternatives or adjuncts to antibiotic therapy, and highlights existing challenges and future research directions for microbiome-based therapeutics.

International journal of food science 2026 PubMed
20 The Immune-Nanomedicine Axis in Glioblastoma: From Biomimetic Delivery to Immune Reprogramming. Shao Y 10.2147/IJN.S655635
View abstract

The therapeutic efficacy against glioblastoma (GBM) remains strictly limited by the blood-brain barrier (BBB) and the profoundly immunosuppressive network of the tumor microenvironment. To overcome these barriers, nanomedicine has shifted from conventional cytotoxin delivery toward the active functional reprogramming of the GBM immune microenvironment. Unlike existing literature that predominantly catalogues nanomaterial properties, this review maps the emerging immune-nanomedicine axis, focusing on recent preclinical proof-of-concept studies to decode how engineered platforms actively reprogram specific cellular compartments within this pathological niche. We evaluate nanoplatforms that utilize biomimetic camouflage and cellular hitchhiking to bypass the BBB and repolarize the myeloid stroma, as well as macroscopic implantable scaffolds designed to immunologically remodel the postoperative resection cavity. To link these innate responses to adaptive immunity, we discuss localized priming niches engineered to rescue dendritic cell cross-presentation. Furthermore, we examine interventions targeting T cell exhaustion-specifically metabolic checkpoint disruption, metalloimmunotherapy, and modalities that synchronize systemic mobilization with deep stromal infiltration. Finally, we review biomimetic and living-cell engineering strategies deployed to direct natural killer cells into the hypoxic tumor parenchyma. Despite robust preclinical data, clinical translation is fundamentally bottlenecked by the scalable manufacturing of complex nanomaterials, severe off-target neuroimmunological toxicities, and inherent physiological constraints of the host. Overcoming these hurdles demands structural minimalism and strict spatiotemporal precision. Ultimately, integrating synthetic biology with advanced 3D microfluidic models provides a necessary framework to bridge the gap between current preclinical achievements and future clinical viability.

International journal of nanomedicine 2026 PubMed
21 Nanotherapeutic Strategies Targeting Senescent Microenvironment for Aging-Related Chronic Diseases. Ma J et al. 10.2147/IJN.S654376
View abstract

DCellular senescence is a central driver of age-related chronic diseases, including neurodegeneration, atherosclerosis, metabolic disorders, and fibrosis. The persistent accumulation of senescent cells and their associated secretory phenotype (SASP) creates a shared microenvironmental basis for disease progression across multiple organ systems. Senolytic and senomorphic strategies targeting senescent cells have shown therapeutic promise, yet their clinical translation remains constrained by insufficient targeting specificity, off-target toxicity, and poor tissue penetration. Nanotechnology-enabled delivery systems offer a programmable approach to overcome these barriers through rationally designed carriers that enable selective recognition of senescent cells, microenvironment-responsive drug release, and enhanced tissue accessibility. This review develops an integrated framework that links nanoplatform design principles to mechanistic intervention categories and disease-specific evidence. We first outline the molecular basis of cellular senescence and its pathological roles in age-related diseases. We then systematically examine four mechanistic dimensions of nanotherapeutic intervention in the senescent microenvironment: redox homeostasis modulation, inflammatory reprogramming, senescent cell clearance, and immune surveillance reactivation. These dimensions target reactive oxygen species, pro-inflammatory cytokines, senescent cells, and immune effector cells, respectively. Representative nanoplatforms applied to neurodegenerative, cardiovascular, metabolic, musculoskeletal, and fibrotic diseases are discussed. We further analyze key translational challenges, including senescent cell heterogeneity, impaired drug delivery in aged tissues, and regulatory uncertainty. Finally, we discuss emerging directions in precision rejuvenation, offering a conceptual framework for the next generation of senescence-targeted nanotherapies.

International journal of nanomedicine 2026 PubMed
22 Development and Validation of a Clinical-Ultrasonographic Model for Differentiating Follicular Thyroid Carcinoma From Adenoma in a Surgically Selected Cohort. Ren M et al. 10.1155/ije/2627742
View abstract

PURPOSE: To identify clinical and ultrasonographic features that distinguish follicular thyroid carcinoma (FTC) from follicular adenoma (FA) and to develop and validate a predictive model for the preoperative risk stratification of follicular neoplasms (FNs). METHODS: In this retrospective study, patients who underwent thyroid surgery due to FNs were consecutively enrolled. The training cohort comprised 142 patients with FA and 48 with FTC diagnosed between January 2016 and December 2022. A temporal validation cohort included 41 FA and 21 FTC cases diagnosed between January 2023 and August 2024. Demographic characteristics, ultrasound features, and serological markers were analyzed using univariate analysis and multivariate logistic regression to identify independent predictors of FTC. A predictive nomogram was constructed based on the identified risk factors. Model performance was evaluated in both cohorts using receiver operating characteristic (ROC) analysis, calibration plots, and decision curve analysis (DCA) to assess discrimination, calibration, and potential clinical utility, respectively. Given the potential interference of thyroglobulin antibody (TgAb) with serum thyroglobulin (Tg) measurements, a subgroup analysis was performed among TgAb-negative patients. This subgroup included 122 FA and 53 FTC patients diagnosed between January 2016 and August 2024. RESULTS: In the predictive model, age (per 10-year increase; odds ratio [OR]: 0.652,  = 0.002), elevated log-transformed serum Tg (OR: 1.271,  = 0.030), larger maximum diameter (per 10-mm increase; OR: 1.744,  < 0.001), hypoechogenicity (OR: 3.188,  = 0.008), and irregularity (OR: 12.295,  < 0.001) were independently associated with FTC. The resulting model showed good discrimination, with areas under the curve (AUCs) of 0.822 (95% confidence interval [CI]: 0.753-0.891) in the training cohort, 0.801 (95% CI: 0.686-0.917) in the temporal validation cohort, and 0.814 (95% CI: 0.745-0.882) in the TgAb-negative sensitivity analysis. Calibration analyses showed generally acceptable agreement between predicted and observed probabilities, although estimates in the temporal validation cohort were imprecise. DCA suggested potential net clinical benefit across a range of threshold probabilities. CONCLUSION: In this surgically selected cohort, the clinical-ultrasonographic model showed potentially useful discrimination between FTC and FA. The model should be regarded as an exploratory risk stratification tool for patients similar to those included in this study. Its applicability to unselected patients with cytologically indeterminate thyroid nodules and its ability to inform decisions for or against diagnostic surgery require prospective external validation.

International journal of endocrinology 2026 PubMed
23 Microhomology-Associated Androgen Receptor Deletion and Enrichment of AR Copy-Number Variants in Androgen Insensitivity Syndrome. Marques JM et al. 10.1155/humu/3178183
View abstract

BACKGROUND: Copy number variations (CNVs) in the androgen receptor () gene are an underrecognized cause of androgen insensitivity syndrome (AIS). Defining their breakpoint architecture and mutational mechanisms may improve diagnosis and genotype-phenotype correlation. OBJECTIVES: To characterize a pathogenic deletion identified in a proband with complete androgen insensitivity syndrome (CAIS) and investigate its mechanism of formation, and to assess the frequency and genomic distribution of CNVs in AIS through a review of published cases and comparison with population data. MATERIALS AND METHODS: Exome sequencing, MLPA, PCR, and Sanger sequencing delineated a hemizygous deletion spanning Exons 6-8 in a 46,XY individual. Breakpoints were mapped with Biostrings/GenomicRanges. We collated CNVs from the literature and curated databases for AIS ( = 991) and contrasted them with CNVs in the general population (gnomAD-SV v4.1.0; = 31,523). Odds ratios and enrichment values were calculated. RESULTS: Breakpoint sequencing revealed an 8-bp microhomology in reverse-complement orientation at the junction, consistent with microhomology-associated deletion. Across 991 AIS cases, 48 carried CNVs, significantly enriched versus controls (OR = 5.08; = 1.14 × 10). Exon 2 was the most frequently involved and strongly associated with CAIS. DISCUSSION: To our knowledge, this is the first report describing breakpoint-associated microhomology in a pathogenic deletion, suggesting a possible role for microhomology-dependent repair. The enrichment of CNVs in AIS supports including CNV detection in the molecular diagnostic workflow. CONCLUSION: CNVs are a clinically relevant, underdetected class of defects in AIS. Integrating CNV detection and precise delineation into diagnostic workflows can enhance diagnostic yield and support genotype-phenotype assessment, whereas breakpoint characterization can provide insights into the mutational mechanisms underlying deletions.

Human mutation 2026 PubMed
24 In Silico, In Vitro, and In Vivo Assessment of Genotoxicity and Cell Transformation Potential of Gardenia Yellow E500. Liang J et al. 10.1002/fsn3.72552
View abstract

Gardenia yellow (GY), a natural food colorant widely used in China, has limited and controversial toxicological evidence, particularly on carcinogenicity and genotoxicity, which hinders its international certification by the Joint FAO/WHO Expert Committee on Food Additives. A high-chromatic-value GY E500 sample was evaluated using an integrated in silico, in vitro, and in vivo strategy following the Integrated Approach to Testing and Assessment framework. Computational predictions of its major components did not identify any consistent evidence for carcinogenicity or genotoxicity. A series of in vitro cell transformation assays, including colony formation, malignant transformation, and soft agar assays, produced no positive findings at 0.1-1 mg/mL, with IC values of 1.038 and 0.9583 mg/mL in SHEE and HaCaT cells, respectively. Genotoxicity was assessed using the Ames, chromosomal aberration, and micronucleus assays according to Chinese national standards and OECD protocols. No dose-related increase in revertant colonies was observed, and the micronucleus assay in mice ( = 10) showed no significant increase at oral doses up to 6.66 g/kg bw. True structural aberrations did not exceed 5.0% at concentrations up to 5000 μg/mL. Overall, under the conditions of this study, GY E500 showed no evidence of genotoxicity or transformation potential, providing additional evidence for its food additive risk assessment.

Food science & nutrition 2026 Nov PubMed
25 Impact of Lifestyle Behaviors and Social Determinants of Health on Breast Cancer Prevention and Survivorship: A Comprehensive Primary Analysis of Patient-Reported Data. Ayers KE et al. 10.1177/15598276261505409
View abstract

Lifestyle behaviors and social determinants of health (SDOH) are critical in breast cancer prevention, survivorship, and recurrence risk, yet adherence to evidence-based recommendations identified by American Society of Clinical Oncology (ASCO) remains variable. This primary cross-sectional study evaluated patient-reported SDOH and lifestyle factors among 700 breast cancer patients receiving care at a large academic oncology clinic between June and August 2023. Data collected through the patient portal included body mass index (BMI), fruit and vegetable intake, physical activity, alcohol consumption, financial insecurity, cancer stage, and hormonal profile as identified by World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR) guidelines. The majority of patients exhibited behaviors inconsistent with WCRF/AICR recommendations. Two-thirds of patients exhibited elevated BMI, 95% reported fewer than 5 daily servings of produce, and mean weekly physical activity was 128 minutes, below recommendation. Only 34% of patients reported no alcohol consumption. In a subgroup analysis of estrogen receptor-positive patients, 47% consumed 4 servings of fruits and vegetables daily, below the recommended ≥5 servings daily. Despite minimal reported financial barriers, adherence to lifestyle recommendations was low, highlighting opportunities for integrating lifestyle medicine and SDOH-informed care into oncology practice to improve cancer outcomes, survivorship, and long-term quality of life.

American journal of lifestyle medicine 2026 Nov 10 PubMed
26 Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy Moushumi Suryavanshi et al. 10.1186/s12885-026-15894-7 BMC Cancer 2026 Scholar
27 Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS). A. Kapoor et al. 10.1200/GO-25-00721 1 citation JCO global oncology 2026 Scholar
28 Resection margin width as a risk factor for liver cancer recurrence M. Kamalova et al. 10.17816/onco703999 Russian Journal of Oncology 2026 Scholar
29 Abstract 1137: Validation of a sensitive, tissue-free blood test for biomarker discovery and tumor burden assessment Zeliang Deng et al. 10.1158/1538-7445.am2026-1137 Cancer Research 2026 Scholar
30 First-line pembrolizumab plus chemotherapy versus bevacizumab plus chemotherapy in response and survival outcomes in PD-L1-negative advanced non-squamous NSCLC: a retrospective comparative cohort study Kuo-Fang Huang et al. 10.21037/tlcr-2026-0917 Translational Lung Cancer Research 2026 Scholar
31 Listening to children's voices: Psychosocial and behavioral experiences and identity-related changes during the cancer trajectory Yi-Pei Cheng et al. 10.1016/j.apjon.2026.101004 Asia-Pacific Journal of Oncology Nursing 2026 Scholar
32 Unveiling trends and clinical progress of immunotherapy for endometrial cancer: a scientometric and clinical trial landscape analysis Ruo-Yan Liu et al. 10.3389/fimmu.2026.1668903 1 citation Frontiers in Immunology 2026 Scholar
33 Non-Diabetic Insulin Use in the Treatment of Neoplasms: A Pilot Study on the Insulin Potentiation Technique and p53 Expression Donato Perez Garcia et al. 10.58489/2836-502x/013 Endocrine System and Diabetes 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Cancer & Oncology
  • Week: November 9 – November 16, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 11:14 PM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —